Table 5.
Summary of Lipid peroxides and nitric oxide analysis in RIN5F treated with BP(Pre-treatment) /DB(Simultaneous) and suboptimal doses of AA (10 μg/ml) + BDNF(50 ng/ml)
| SUMMARY OF THE ANALYSIS OF LIPID PEROXIDES AND NITRIC OXIDE LEVELS IN RIN5F CELLS TREATED WITH DB/BP | |||||
|---|---|---|---|---|---|
| CHEMICAL | GROUP | LIPID PEROXIDES (μM TMOP) | NITRIC OXIDE (μM Nitrite) | ||
| Supernatant Lysates | Supernatant Lysates | ||||
| DOXORUBICIN | CONTROL | 0.43 ± 0.03 | 1.1 ± 0.03 | 0.71 ± 0.02 | 0.9 ± 0.03 |
| DB(100 ng/ml) | 0.75 ± 0.02 | 1.8 ± 0.04 | 0.91 ± 0.04 | 1.2 ± 0.03 | |
| AA(10 μg/ml) | 0.23 ± 0.02 | 1.1 ± 0.03 | 0.49 ± 0.02§ | 1.2 ± 0.02§ | |
| BDNF(50 ng/ml) | 0.37 ± 0.02 | 1.3 ± 0.04 | 0.41 ± 0.01 | 1.2 ± 0.06 | |
| AA + BDNF | 0.48 ± 0.01 | 1.1 ± 0.09 | 0.39 ± 0.01 | 1.2 ± 0.04 | |
| DB + AA(10 μg/ml) | 0.55 ± 0.04# | 1.2 ± 0.05 | 1.02 ± 0.02# | 1.1 ± 0.04 | |
| DB + BDNF | 0.61 ± 0.03§ | 0.87 ± 0.02§ | 0.91 ± 0.01§ | 0.88 ± 0.08§ | |
| DB + AA + BDNF | 0.59 ± 0.03 | 1.2 ± 0.06 | 0.79 ± 0.03 | 1.1 ± 0.05 | |
| BENZOPYRENE | CONTROL | 0.58 ± 0.02 | 0.8 ± 0.02 | 0.74 ± 0.02 | 0.98 ± 0.05 |
| BP(1.5 mM) | 0.99 ± 0.01 | 1.6 ± 0.03 | 0.99 ± 0.03 | 1.4 ± 0.06 | |
| AA(10 μg/ml) | 0.61 ± 0.04 | 1.1 ± 0.03 | 0.69 ± 0.01 | 1.11 ± 0.02 | |
| BDNF(50 ng/ml) | 0.59 ± 0.02 | 0.89 ± 0.01 | 0.61 ± 0.03 | 1.07 ± 0.03 | |
| AA + BDNF | 0.61 ± 0.01 | 1.2 ± 0.02 | 0.72 ± 0.01 | 1.09 ± 0.04 | |
| BP + AA(10 μg/ml) | 0.69 ± 0.05# | 0.89 ± 0.04# | 0.69 ± 0.07# | 1.05 ± 0.02# | |
| BP + BDNF | 0.72 ± 0.03§ | 0.7 ± 0.05§ | 0.71 ± 0.4§ | 1.1 ± 0.07§ | |
| BP + AA + BDNF | 0.64 ± 0.06 | 1.1 ± 0.02 | 0.79 ± 0.01 | 1.23 ± 0.03 | |
Lipid peroxides formed are expressed as μmoles of TMOP formed; Nitric oxide formed is expressed as μ moles of nitrite formed. *P < 0.01 Vs Untreated control and § P ≤ 0.05, # P ≤ 0.02, * P < 0.01, ** P < 0.001 Vs DB/BP -treated group